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Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a
heterogeneous entity with relevant long-term major cardiovascular events. Several trials
have demonstrated that dual antiplatelet therapy (DAPT), b-blocker, renin-angiotensin-
aldosterone system (RAAS) inhibitor and statin therapy improve the prognosis in patients
with obstructive myocardial infarction (ob-MI). However, evidence on the best medical
therapy for secondary prevention in MINOCA patients is lacking.
Purpose: To investigate the effects of secondary prevention treatments at discharge on
mid-term outcomes in MINOCA.
Methods: Patients with acute myocardial infarction (MI) undergoing early coronary
angiography between 2016 and 2018 were extracted from a clinical database. The
diagnosis of MINOCA was made according to 2016 ESC MINOCA Position Paper criteria.
Second-level diagnostic work-up including cardiac magnetic resonance was performed
to exclude non-ischemic troponin elevation cause. The relationship between treatments
and outcomes was evaluated by using Kaplan-Meier survival analysis and Cox regression
models. All confirmed MINOCA were followed in our outpatient clinics. The primary end-
points were all-cause mortality, re-hospitalization for MI and a composite outcome
including all-cause mortality, hospitalization for MI and ischemic stroke (MACE).
Results: Out of 1,141 AMI who underwent coronary angiography, 134 were initially
diagnosed as MINOCA. Patients with MINOCA were less likely to receive secondary
prevention treatments than patients with obstructive coronary artery disease (CAD) MI
(respectively, 42.1% vs 81.8% for DAPT; 75.5% vs 89.6% for b-blockers; 64.7% vs
80.3% for RAAS inhibitor and 63.9% vs 83% for statins). Based on the diagnostic work-up
completed during the first month after discharge, a final sample of 88 patients had
confirmed MINOCA. During an average follow-up of 19.35 ± 10.65 months, all-causein.org January 2020 | Volume 10 | Article 16061
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Frontiers in Pharmacology | www.frontiersmortality occurred in 11 (12.5%) patients, recurrence of MI in 4 (4.5%), and MACE in 15
(17.0%) patients. Patients treated with RAAS inhibitors and statins had a significantly
longer survival. On the contrary, no increase in survival was found in patients treated with
b-blockers or DAPT. Cox multivariable analysis, including all secondary prevention drugs,
showed that only RAAS inhibitors were associated with reduced all cause-mortality
and MACE.
Conclusion: This prospective study suggests that RAAS inhibitor therapy provides mid-
term beneficial effects on outcomes in MINOCA patients; in contrast, dual antiplatelet, b-
blocker and statin therapy had no effects on mortality and MACE. These results should be
considered preliminary and warrant confirmation from larger studies.Keywords: myocardial infarction with non-obstructive coronary arteries (MINOCA), secondary prevention medical
therapy, prognosis, RAAS inhibitors, b-blockers, statins, dual antiplatelet therapy (DAPT)INTRODUCTION
The 2018 ESC guidelines of the Fourth Universal definition of
myocardial infarction (MI) differentiated myocardial infarction
from myocardial injury and defined acute myocardial infarction
with non-obstructive coronary arteries (MINOCA). According
to the pathophysiological mechanisms, MINOCA were located
between type I and type II MI: type 1 MI caused by
atherosclerotic plaque disruption, and type 2 MI due to non
athero-thrombosis plaque (epicardial coronary vasospasm,
c o r o n a r y m i c r o v a s c u l a r d y s f u n c t i o n , c o r o n a r y
thromboembolism, spontaneous coronary artery dissection,
supply-demand mismatch) (Thygesen et al., 2019).
The diagnosis of MINOCA includes the criteria for acute MI,
no evidence of angiographic coronary obstruction (coronary
stenosis <50%) and of a clinically apparent alternative diagnosis
for the acute presentation (Agewall et al., 2017). In this definition,
both patients with normal coronary arteries (without coronary
atheromasia) and those with coronary atheromasia up to 50% are
included (Rossini et al., 2013). Moreover, the third condition
differentiating MINOCA is that it occurs in an ischemia setting,
excluding other causes of non-ischemic troponin elevation (eg
sepsis, pulmonary embolism, myocarditis).
Similarly to heart failure, MINOCA should be considered as a
“working diagnosis” that requires further evaluation to investigate
its underlying mechanisms, with important diagnostic and
prognostic implications on secondary prevention therapy.
Consequently, the term MINOCA designates a heterogeneous
subgroup of patients with myocardial infarction, with the afore-
mentioned characteristics, rather than a specific pathophysiological
mechanism (Tamis-Holland et al., 2019).
Nowadays, the prevalence of MINOCA is estimated at 5–8%,
with variations depending on the proportion of patients with MI
who performed coronary angiography and on the high-sensitivity
cardiac troponin (hs-cTn) assays used (Pasupathy et al., 2015).
Literature prognosis data showed thatMINOCA is not a benign
condition, with an overall estimated mortality around 3.5–4.5%
(Pasupathyet al., 2015;Baronet al., 2016;Pizzi et al., 2016;Barr etal.,
2018). This unfavorable outcome might be explained, at least inin.org 2part, by the low rate of b-blockers, angiotensin converting enzyme
inhibitors (ACEI), statins, and antiplatelet drugs prescription.
Moreover, most drugs used for secondary prevention in
patients with myocardial infarction and obstructive coronary
arteries are aimed at atherosclerotic disease prevention, that is a
minor problem in MINOCA. Therefore, doubts have been raised
about the use of standard therapy.
In three observational studies, ACEI/angiotensin Receptor
Blockers (ARB) therapy has demonstrated a beneficial effect on
outcome in patients with MINOCA (Manfrini et al., 2014;
Lindahl et al., 2017; Choo et al., 2019). However, these studies
have some potential biases, such as the diagnosis of MINOCA
that includes other conditions without acute ischemia, and the
long period of enrolment in which the diagnostic criteria of MI
were refined. Therefore, we investigated prospectively the
association between antiplatelet therapy, renin-angiotensin-
aldosterone system (RAAS) inhibitors, b-blockers and statins
and mid-term cardiovascular events in MINOCA patients.MATERIALS AND METHODS
Study Population
Out of 1,523 consecutive patients with acute myocardial infarction
admitted between January 2016 and December 2018 to Bologna
University Hospital (Policlinico Sant'Orsola-Malpighi), 1,141
underwent coronary angiography (CAG) within the first 48 h of
the index hospitalization. According to the extent of stenosis,
patients were classified into three groups: a) obstructive CAD
(ob-CAD), defined as a stenosis ≥50% of the lumen diameter in
at least one coronary artery, b) non-obstructive CAD (non ob-
CAD), defined as a stenosis 1–49% of the coronary artery diameter,
and (c) normal coronary arteries (NCA), defined as no
angiographic visible stenosis or atheromasia. The MINOCA
diagnosis was performed according to 2016 ESC MINOCA
Position Paper criteria (Agewall et al., 2017).
We excluded patients who did not perform coronary
angiography or performed it after 48 h of hospital admission and
patients with previous coronary revascularization (Figure 1).January 2020 | Volume 10 | Article 1606
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For each patient, demographic and baseline clinical data were
collected, including sex, age, height, weight, body mass index
(BMI), cardiovascular risk factors, family history of
cardiovascular disease, and first admission diagnosis. We also
collected information on major epicardial coronary arteries
obstruction, based on visual assessment during acute CAG
performed by an expert interventional cardiologist. Discharge
medications were also recorded (antiplatelet, b-blockers, RAAS
inhibitors and statins). Antiplatelet therapy was prescribed
according to the current guideline recommendations
(Valgimigli et al., 2018).
A standard 12-lead ECG was performed and laboratory
testing was carried out in all patients, including hemoglobin
and creatinine. The glomerular filtration rate was calculated
using CKD-EPI formula.
All patients underwent 2D-echocardiogram and the left
ventricular ejection fraction (LVEF) was calculated, according
to European recommendations (Lang et al., 2015).
During hospitalization or within 1-month of discharge,
patients underwent contrast cardiac magnetic resonance
(CMR) and/or pulmonary and vascular computed tomography
in order to exclude non-ischemic troponin elevation causes
(Tamis-Holland et al., 2019).Moreover, patients who did not
complete the diagnostic work-up and those who died during the
index hospitalization were excluded from the analysis.Frontiers in Pharmacology | www.frontiersin.org 3Ethics
Our data are collected as part of an approved protocol regarding
the observational study “Acute Myocardial Infarction; Prognostic
and Therapeutic Evaluation” (ClinicalTrials.gov Identifier:
NCT03883711). All patients were treated in accordance with
the Declaration of Helsinki; all of them were informed about their
participation in the registry and provided informed consent for
the anonymous publication of scientific data.
Primary Outcomes
The primary outcomes were all-cause mortality, re-hospitalization
for MI and a composite outcome including all-cause mortality,
hospitalization for MI and ischemic stroke (MACE). Myocardial
infarction was diagnosed according to current ESC guidelines; (1)
stroke was defined as an ischemic cerebral infarction caused by
embolic or thrombotic occlusion of a major intracranial artery.
The main purpose of this study was to compare the effects of
secondary prevention treatments (antiplatelet, b-blockers, RAAS
inhibitors, and statins) prescribed at discharge on mid-
term prognosis.
Mid-Term Follow-Up
Patients were followed from discharge through outpatient
clinical visits or telephone interviews every 6 months until the
end of follow-up. During the follow-up visit, each patient
underwent ECG, echocardiogram and was clinically evaluatedFIGURE 1 | Study flow-chart. AMI: acute myocardial infarction; CAD, coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries.January 2020 | Volume 10 | Article 1606
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and the clinical end-points.
Statistical Analyses
Patient characteristics were summarized using mean ± standard
deviation for continuous variables and absolute and percentage
frequencies for categorical variables. Patient subgroups were
compared using c² test or Fisher’s exact test for categorical
variables and t-test or Mann-Whitney test for continuous
variables, as appropriate.
Patients’ survival at 36 months was obtained using Kaplan-
Meier estimates and compared between subgroups using log-
rank test. Univariate and multivariable Cox proportional-hazard
models were used to analyze the association of pharmacological
treatments with death, re-infarction, stroke and MACE (either of
the three major cardiovascular events).RESULTS
Out of 143 patients with non-obstructive CAD or normal
coronary arteries, 9 were excluded because a non-ischemic
troponin elevation cause was found (e.g. sepsis, pulmonary
embolism, myocarditis) during hospitalization. The diagnosisFrontiers in Pharmacology | www.frontiersin.org 4of MINOCA was made at discharge in 134 patients. Forty-one
patients were further excluded because the diagnosis was not
confirmed by second-level instrumental examination performed
after discharge or for incomplete diagnostic work-up and 5
patients were not traced at follow-up. The final sample used to
analyze the effects of secondary prevention treatments on
outcomes consisted of 88 patients (Figure 1).
MINOCA Versus Obstructive Coronary
Artery Disease: Demographic and Clinical
Characteristics
We first compared the characteristics of patients with MINOCA
and those with obstructive CAD (ob-CAD). Patients with
MINOCA were younger, more frequently female, and had less
frequently hypertension, dyslipidemia and type-2 diabetes than
patients with ob-CAD (Table 1). Moreover, MINOCA patients
were less likely to have a medical history of previous MI (7.7% vs.
25% in ob-CAD) and had significantly higher LVEF and
glomerular filtration rate.
Overall, the diagnosis of ST-Elevation Myocardial Infarction
at baseline was markedly less frequent among MINOCA vs ob-
CAD patients (18.9%, versus 49.8%, respectively).
Of the 134 MINOCA patients (Table 2), only 22 had non-
obstructivecoronary stenosis, 19patientshadone-vessel, 2had two-TABLE 1 | Baseline characteristics and drug prescription at discharge in MINOCA patients' vs obstructive CAD patients.
MINOCA
Patients
(N = 134)
Obstructive CAD
Patients
(N = 998)
P-value
Age years, mean (SD) 65.73 (14.03) 69.13 (12.6) 0.017
Females, n (%) 79 (59) 304 (30.5) <0.001
BMI kg/m2, mean (SD) 27.16 (4.52) 27.12 (4.88) 0.89
Cardiovascular risk factors
Current/past smoking, n (%)
73 (54.9) 622 (63.2) 0.063
Hypertension, n (%) 82 (61.7) 759 (77) <0.001
Dyslipidemia, n (%) 82 (61.7) 701 (71) 0.028
Type-2 diabetes, n (%) 14 (10.5) 239 (24.2) <0.001
Medical history
Previous MI, n (%)
9 (7.7) 244 (Tzanidis et al., 2001) <0.001
Previous stroke, n (%) 9 (6.7) 94 (9.4) 0.31
Atrial fibrillation, n (%) 8 (Barr et al., 2018) 87 (8.8) 0.28
Admission diagnosis
STEMI, n (%)
23 (18.9) 457 (49.8) <0.001
Laboratory parameters
GFR CKD-EPI ml/min, mean (SD)
75.09 (23.19) 70.37 (23.18) 0.029
Hemoglobin g/dl, mean (SD) 13.46 (1.75) 13.47 (2.15) 0.99
Echocardiogram
LVEDV ml, mean (SD)
90.64 (25.80) 108.29 (40.30) 0.046
% EF, mean (SD) 55.67 (11.01) 52.02 (10.99) 0.001
Medical Therapy at discharge
Single antiplatelet, n (%)
101 (75.9) 899 (94.6) <0.001
ASA, n (%) 98 (73.7) 867 (89.6) <0.001
P2Y12 inhibitor, n (%) 60 (45.1) 824 (85.1) <0.001
Dual antiplatelet therapy, n (%) 56 (42.1) 787 (81.1) <0.001
Beta-blockers, n (%) 100 (75.2) 855 (89.6) <0.001
RAAS inhibitor, n (%) 86 (64.7) 779 (80.3) <0.001
Statins, n (%) 85 (63.9) 792 (83) <0.001January 2020 | Volume 10 | ArtBMI, body mass index; MI, myocardial infarction; STEMI, ST elevation myocardial infarction; NSTEMI, non ST elevation myocardial infarction; GFR, glomerular filtration rate; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; CRP, C-reactive Protein; LVEDd, left ventricular end diastolic diameter; LVEDV, left ventricular end diastolic volume; EF, ejection
fraction; RAAS, renin-angiotensin-aldosterone system; SD, Standard deviation.
Chi-square test for categorical variables; Student's t-test for normally distributed continuous variables and Mann-Whitney test and for non-normally distributed continuous variables.icle 1606
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higherprevalenceof three-vessel and leftmainwas found inpatients
with obstructive myocardial infarction. The mean percentage of
coronary stenosis in MINOCA patients was 12.7%.
MINOCA patients were then classified into non ob-CAD and
NCA patients. No significant difference in baseline clinical
characteristics (Table 3) was found between these subgroups.
Therefore, in the subsequent analyses, MINOCA patients were
considered as a whole.
MINOCA Versus Obstructive Coronary
Artery Disease: Secondary Prevention
Medical Therapy
At discharge, 75.9% patients with MINOCA were treated with a
single antiplatelet drug (aspirin or P2Y12 inhibitor) and only 42.1%
with dual antiplatelet therapy (DAPT), compared with 94.6% and
81.8% ob-CAD patients. Similarly, the percentage of MINOCA
patients treated with b-blockers, RAAS inhibitor and statins was
lower compared with ob-CAD (75.5, 64.7, and 63.9% vs 89.6, 80.3,
and 83%, respectively) (Table 1). Secondary prevention medical
therapy was prescribed in a relatively low proportion of non-ob
CAD patients, with coronary plaques (range 63.6–90.9%), and of
NCA patients (range 51.5–86.4%) (Table 3).
MINOCA Prognosis
During an average follow up of 19.35 ± 10.6 months), all-cause
death occurred in 11 (12.5%) patients, re-MI in 4 (4.5%) patients,
and MACE in 15 (17%). No ischemic stroke was observed.
Interestingly, all-cause death and recurrent MI were more
frequent among patients with NCA than among patients with
ob-CAD (15.2 and 6.1% vs 4.5 and 0%, respectively), although
this difference was not statistically significant.
Concerning medications, RAAS inhibitors and statins were
the only treatments significantly associated with longer survival
in a Kaplan-Meier analysis (Figure 2). In univariate Cox
regression analyses, a reduced risk of all-cause mortality and
MACE was found in patients using RAAS inhibitors (Table 4).Frontiers in Pharmacology | www.frontiersin.org 5In a multiple Cox regression analysis including RAAS inhibitors,
statins, single antiplatelet therapy (aspirin or P2Y12 inhibitors),
DAPT, b-blockers in the model with a forward stepwise
procedure, none of these drugs except RAAS inhibitors was
associated with lower mortality or with MACE. In contrast, no
significant benefit was associated with the use of b-blockers,
DAPT or single antiplatelet therapy SAPT (both aspirin or
P2Y12 inhibitor).DISCUSSION
This is the first prospective study to evaluate the association
between secondary prevention drugs and mid-term outcomes in
a selected cohort of patients with MINOCA. Among 88
consecutive MINOCA patients admitted between 2016 and
2018 and followed for an average of 19 months, we found a
significantly lower risk of MACE and all-cause of mortality in
patients treated with RAAS inhibitors.TABLE 2 | Results of coronary angiography in MINOCA versus obstructive CAD
patients.
MINOCA
(N = 134)
Obstructive CAD
(N = 998)
P-value
One vessel disease, n (%) 19 (14.2%) 631 (63.2%) <0.001
Two vessel disease, n (%) 2 (1.5%) 235 (23.5%) <0.001
Three vessel disease, n (%) 1 (0.7%) 132 (13.2%) <0.001
Mean stenosis % (SD) 12.7% ( ± 19.5) 85.2% ( ± 28.9) <0.001
Coronary vessel
Left main CAD, n (%) 8 (6.0%) 176 (17.6%) 0.001
LAD CAD, n (%) 18 (13.4%) 492 (49.3%) <0.001
ID CAD, n (%) 3 (2.2%) 160 (16%) <0.001
LCx CAD, n (%) 5 (3.7%) 207 (20.7%) <0.001
OM CAD, n (%) 5 (3.7%) 183 (18.3%) <0.001
RCA CAD, n (%) 9 (6.7%) 369 (37%) <0.001CAD, coronary artery disease; LAD, left anterior descending artery; ID, first diagonal
branch; LCx, left circumflex artery; OM obtuse marginal branches; MINOCA, Myocardial
infarction with non-obstructive coronary arteries; RCA, right coronary artery.TABLE 3 | Baseline characteristics and drug prescription at discharge in
MINOCA sub-groups.
Non-obstruc-
tive
CAD Patients
(N = 22)
Normal coro-
nary
arteries Patients
(N = 66)
P-
value
Age years, mean (SD) 69.32 (10.45) 66.63 (14.17) 0.59
Gender female, n (%) 13 (59.1) 42 (63.6) 0.70
BMI kg/m2, mean (SD) 25.68 (4.73) 25.65 (4.05) 0.98
Cardiovascular risk factors
Current/past smoking, n (%)
12 (54.5) 33 (50.8) 0.76
Hypertension, n (%) 14 (63.6) 46 (70.8) 0.53
Dyslipidemia, n (%) 15 (68.2) 46 (70.8) 0.82
Type-2 diabetes, n (%) 3 (13.6) 8 (12.3) 0.87
Medical history
Previous MI, n (%)
1 (5.3) 10 (19.2) 0.15
Previous stroke, n (%) 2 (9.1) 6 (9.1) 1.0
Atrial fibrillation, n (%) 2 (9.1) 4 (6.2) 0.64
Admission diagnosis
STEMI, n (%)
4 (19.0) 8 (13.1) 0.51
Laboratory parameters
GFR CKD-EPI ml/min, mean
(SD)
72.62 (24.02) 73.71 (23.46) 0.76
Hemoglobin g/dl, mean (SD) 13.33 (1.94) 13.51 (1.75) 0.73
Echocardiogram
LVEDV ml, mean (SD)
87.67 (25.24) 87.46 (25.67) 0.97
% EF, mean (SD) 57.78 (13.63) 57.27 (7.92) 0.51
Medical Therapy at discharge
Single antiplatelet, n (%)
20 (90.9) 57 (86.4) 0.58
ASA, n (%) 19 (86.4) 56 (84.8) 0.86
P2Y12 inhibitor, n (%) 17 (77.3) 37 (56.1) 0.07
Dual antiplatelet therapy, n (%) 16 (72.7) 34 (51.5) 0.08
Beta-blockers, n (%) 20 (90.9) 57 (86.4) 0.58
RAAS inhibitor, n (%) 14 (63.6) 49 (74.2) 0.34
Statins, n (%) 18 (81.8) 48 (72.7) 0.39January 2020 | Volume 10 | ArtiBMI, body mass index; MI, myocardial infarction; STEMI, ST elevation myocardial infarction;
NSTEMI, non ST elevation myocardial infarction; GFR, glomerular filtration rate; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; CRP, C-reactive Protein; LVEDd, left
ventricular end diastolic diameter; LVEDV, left ventricular end diastolic volume; EF, ejection
fraction; RAAS, renin-angiotensin-aldosterone system; SD, Standard deviation.
Chi-square test for categorical variables; Student's t-test for normally distributed continuous
variables and Mann-Whitney test and for non-normally distributed continuous variables.cle 1606
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Nowadays with the common use of coronary angiography in MI,
clinicians are regularly confronted with MINOCA which
represents a puzzling diagnosis, including heterogeneous
patients with many potential etiologies that need to be
investigated. In the literature, the prevalence of MINOCA is
estimated around 6–8% among patients diagnosed with MI.(5)
The rate of MINOCA depends largely on the proportion of
patients with MI who performed CAG and on hs-cTn
assays used.
In our study the prevalence of MINOCA is around 12%; a
possible reason for this discrepancy is that 75% of our patients
with acute MI underwent CAG. Indeed, not all patients
presenting without ST-segment elevation acute coronaryFrontiers in Pharmacology | www.frontiersin.org 6syndromes (ACS) undergo coronary angiography, which may
lead to a selection bias (De Ferrari et al., 2014). In fact, if
coronary angiograms were increasingly performed in patients
with acute myocardial infarction, a higher number of non-
obstructive CAD, would be detected.
MINOCA long-term prognosis is not event-free, with an
approximate 9.2% rate of MACE per year (Baron et al., 2016;
Pizzi et al., 2016; Choo et al., 2019). Interestingly, Kang et al.
confirmed that 12-month major adverse cardiac events (death and
myocardial infarction) in patients withMINOCAwere comparable
to those of patients withMI associatedwith single- or double-vessel
coronary artery disease (Kang et al., 2011). Our data regarding
MACE are consistent with the literature: we observed about 17%
MACE events during the follow-up, which underscores the
importance of secondary prevention medical therapy.
Secondary Medical Therapy Prevention:
Under-Prescribed or Not Targeted?
Many clinical studies suggested that MINOCA is an
undertreated population; (Ramanath et al., 2010; De Ferrari
et al., 2011; Pizzi et al., 2016) however no randomized clinical
trial carried out in this population showed that secondary
prevention drugs improve the prognosis of these patients.
Consequently, discharging MINOCA patients is challenging
for physicians due to the lack of guidelines regarding optimal
treatment. Thus, in the absence of a clear alternative, clinicians
tend to prescribe atherosclerotic prevention medication. ThisTABLE 4 | Secondary prevention therapy and outcomes.
TOTAL
N = 88
MACE
HR (95% CI)
Death
HR (95% CI)
Re-MI
HR (95% CI)
ASA 0.80 (0.23–2.85) 0.93 (0.20–4.33) 0.56 (0.06–5.43)
P2Y12 Inhibitor 0.82 (0.30–2.27) 0.85 (0.26–2.78) 0.73 (0.10–5.19)
DAPT 0.42 (0.14–1.24) 0.48 (0.14–1.64) 0.28 (0.03–2.73)
B-blockers 0.43 (0.14–1.35) 0.67 (0.14–3.09) 0.17 (0.02–1.22)
RAAS Inhibitors 0.29 (0.10–0.81) 0.20 (0.06–0.70) 0.78 (0.08–7.99)
Statins 0.44 (0.16–1.22) 0.31 (0.09–1.01) 1.26 (0.13–12.15)The associations, HR (95% CI), between treatments and outcomes. CI, confidence interval;
HR, hazard ratio; DAPT, dual antiplatelet therapy; RAAS, renin-angiotensin-aldosterone
system; MACE, major adverse cardiac events; re-MI, acute myocardial infarction.FIGURE 2 | Kaplan-Meier survival curves in MINOCA patients according to treatment with secondary prevention drugs. (A), DAPT; (B), RAAS inhibitors
(angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB); (C), statins; (D), B-blockers.January 2020 | Volume 10 | Article 1606
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patients with coronaries obstruction and cannot be extended to
MINOCA patients, which represent a different population.
Moreover, most drugs used for secondary prevention in
patients with MI and obstructive CAD are aimed at
counteracting atherosclerotic progression, that constitutes a
minor problem in MINOCA in which atherosclerotic plaque
disruption is only one of the several related underlying etiologies.
Thus, the crucial issue is whether the prognosis of these
patients is not event-free because they are under-treated or
because the prescribed drugs are not targeted for this category
of patients. Probably, both previous statements are true; in fact,
our study confirmed that RAAS inhibitors were the only drug
significantly associated with lower all-cause mortality and
MACE; in contrast, b-blockers and anti-platelet agents had
apparently no effects on outcomes.
The long- term cardiovascular protection conferred by
angiotensin-converting enzyme inhibitor-mediated was strongly
supported by the results of the Heart Outcomes Prevention
Evaluation (HOPE) trial, indicating a significant relative risk
reduction in the combined endpoint of cardiovascular death, MI
and stroke or cardiac arrest (Yusuf et al., 2000). ESC guidelines
recommend the use of RAAS-blockers for effective protection of
patients with and without ST-segment elevation MI (Roffi et al.,
2016; Ibanez et al., 2018).
The beneficial effects of RAAS inhibitors were already
demonstrated in patients with non-obstructive coronary artery
disease, however these studies had some limitations such as the
definitionofMINOCAand inclusionofpatientswithnon-ischemic
troponin elevation cause.(9,10,11) Our study confirms that RAAS
inhibitors are beneficial in selected patients who meet the 2016
ESC MINOCA Position Paper criteria (Agewall et al., 2017).
The RAAS inhibitors block the ACE-mediated formation of
angiotensin (Ag) II (ACE-I) and the linkage of Ag II to receptor
type 1 (AT1) (ARBs), in the circulation and peripheral tissues,
producing blood pressure lowering, sympathetic inhibition, anti-
atherosclerotic, and anti-thrombotic effects(10). In fact, RAAS
inhibitors reduce macrophage accumulation, increase
bradykinin bioavailability, improving non-endothelial and
endothelial dependent coronary microvascular function (Pizzi
et al., 2004; Artom et al., 2014). Additionally, they exhibit
positive anti-fibrotic effects on the myocardium, by inhibiting
macrophage-related inflammation, reducing oxidative stress and
transforming growth factor beta (TGF-B) synthesis which is
associated with cardiac fibroblast proliferation, collagen
deposition, scar formation and cardiac fibrosis (Sun et al.,
1998; Tzanidis et al., 2001; Lu et al., 2004).
The “pleiotropic” effects of RAAS inhibitors on the
cardiovascular system and their various possible pathways
support their benefit for MINOCA patients, a heterogeneous
population with different etiology.
As regards statins, survival analysis indicates that they are
associated with mortality reduction. The plausible mechanism
explaining this effect is the slowdown of the progress of
atherosclerotic process and plaque stabilization; (AmbroseFrontiers in Pharmacology | www.frontiersin.org 7et al., 1988) this is especially true in MINOCA patients with
mild CAD because plaque disruption can also occur in non-
significant plaques. In addition, statins might be beneficial in
MINOCA patients through their protective effects on endothelial
function (Calabrò and Yeh, 2005).
Although findings from the literature indicate a significant
risk reduction in patients with obstructive CAD treated with b-
blockers and anti-platelets therapy, no benefits were proved in
MINOCA patients. Probably, the many etiopathogenic
mechanisms in the absence of athero-thrombotic phenomena
associated with complicated plaque and coronary stents support
the lack of benefit in antiplatelet prescription. The PROSPECT
study demonstrated that ACS occurs from atheroma with
definite histopathologic characteristics that are not necessarily
dependent on the degree of angiographic stenosis (Stone et al.,
2011; Rossini et al., 2013; Crea and Libby, 2017). Indeed, in
patients with non-obstructive CAD, activated leukocytes,
endogenous fibrinolysis, vasospasm, and embolism are possible
mechanisms of acute ischemia without plaque disruption.Study Limitations
First, although the prevalence of our population is consistent
with that observed in the literature, the number of patients with
non-obstructive CAD is relatively small; thus the study is not
adequately powered to detect the effect of secondary prevention
drugs. Thus, our results should be considered preliminary and
warrant confirmation in larger prospective samples. Second, no
information was available on the staging and duration of comorbid
diseases (i.e.: hypertension, diabetes), and onmedication use before
hospitalization,which prevents amore detailed investigation on the
impact of each comorbidity on outcomes.
Third, angiographic data were retrieved from clinical records
and were not adjudicated by a core laboratory, having some
degree of between-person variability.
Fourth, no intracoronary investigation other than coronary
angiography was performed. Fractional flow reserve or
intravascular imaging techniques, like intravascular ultrasound or
optical coherence tomography, would likely increase
atherosclerotic plaque detection, not visible on CAG (Montone
et al., 2018; Rahman et al., 2019).Nowadays, fractional flow reserve
(FFR) is used to determine the hemodynamic relevance of coronary
artery stenosis. The FAMOUS-NSTEMI trial demonstrated that
about 7% of coronary lesions with a stenosis severity of 30–49% in
NSTEMI patients exhibited a functional significant (FFR ≤ 0.80)
stenosis (Layland et al., 2015). In our studywedid not evaluate FFR;
however, in our cohort only one third of non-obstructiveMINOCA
patients presented coronary stenosis severity between 30 and 49%.
However, this study reflects the everyday clinical practice in the vast
majority of experienced coronary angiography laboratories
worldwide, where the use of such techniques is limited due to
cost, procedure time and contrast load. Additionally, this “non-
atherosclerotic” approach is incomplete because coronary spasm
and thrombosismayoccur also in the absenceof atherosclerosis and
it may be an “innocent bystander” in myocardial injury.January 2020 | Volume 10 | Article 1606
Paolisso et al. Secondary Prevention Therapy in MINOCACONCLUSION
Our data support that treatment with RAAS inhibitor provides
mid-term beneficial effects on outcomes in patients with
MINOCA; in contrast, we did not find an effect of dual
antiplatelet, b-blocker and statin therapy. Our results should be
interpreted with caution because the study is under-powered to
detect drug effects in a population with a small event rate.
Multicenter prospective adequately powered studies targeting
this specific population and the potential benefit of guideline-
recommended therapies are warranted.DATA AVAILABILITY STATEMENT
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